These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1076 related items for PubMed ID: 29082835

  • 1. Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia.
    Ribera JM.
    Expert Rev Hematol; 2017 Dec; 10(12):1057-1067. PubMed ID: 29082835
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Safety and efficacy of blinatumomab: a real world data.
    Apel A, Ofran Y, Wolach O, Shimony S, Ram R, Levi I, Zektser M, Koren-Michowitz M.
    Ann Hematol; 2020 Apr; 99(4):835-838. PubMed ID: 32076826
    [Abstract] [Full Text] [Related]

  • 4. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.
    Topp MS, Kufer P, Gökbuget N, Goebeler M, Klinger M, Neumann S, Horst HA, Raff T, Viardot A, Schmid M, Stelljes M, Schaich M, Degenhard E, Köhne-Volland R, Brüggemann M, Ottmann O, Pfeifer H, Burmeister T, Nagorsen D, Schmidt M, Lutterbuese R, Reinhardt C, Baeuerle PA, Kneba M, Einsele H, Riethmüller G, Hoelzer D, Zugmaier G, Bargou RC.
    J Clin Oncol; 2011 Jun 20; 29(18):2493-8. PubMed ID: 21576633
    [Abstract] [Full Text] [Related]

  • 5. Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia.
    Le Jeune C, Thomas X.
    Drug Des Devel Ther; 2016 Jun 20; 10():757-65. PubMed ID: 26937176
    [Abstract] [Full Text] [Related]

  • 6. Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.
    Aldoss I, Bargou RC, Nagorsen D, Friberg GR, Baeuerle PA, Forman SJ.
    Leukemia; 2017 Apr 20; 31(4):777-787. PubMed ID: 28028314
    [Abstract] [Full Text] [Related]

  • 7. CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy.
    Pillai V, Muralidharan K, Meng W, Bagashev A, Oldridge DA, Rosenthal J, Van Arnam J, Melenhorst JJ, Mohan D, DiNofia AM, Luo M, Cherian S, Fromm JR, Wertheim G, Thomas-Tikhonenko A, Paessler M, June CH, Luning Prak ET, Bhoj VG, Grupp SA, Maude SL, Rheingold SR.
    Blood Adv; 2019 Nov 26; 3(22):3539-3549. PubMed ID: 31738832
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Phase 1b/2 study of blinatumomab in Japanese adults with relapsed/refractory acute lymphoblastic leukemia.
    Kiyoi H, Morris JD, Oh I, Maeda Y, Minami H, Miyamoto T, Sakura T, Iida H, Tuglus CA, Chen Y, Dos Santos C, Kalabus J, Anderson A, Hata T, Nakashima Y, Kobayashi Y.
    Cancer Sci; 2020 Apr 26; 111(4):1314-1323. PubMed ID: 31971321
    [Abstract] [Full Text] [Related]

  • 15. Blinatumomab, a Bispecific T-cell Engager (BiTE(®)) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications.
    Zhu M, Wu B, Brandl C, Johnson J, Wolf A, Chow A, Doshi S.
    Clin Pharmacokinet; 2016 Oct 26; 55(10):1271-1288. PubMed ID: 27209293
    [Abstract] [Full Text] [Related]

  • 16. Blinatumomab: Bridging the Gap in Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia.
    Folan SA, Rexwinkle A, Autry J, Bryan JC.
    Clin Lymphoma Myeloma Leuk; 2016 Aug 26; 16 Suppl():S2-5. PubMed ID: 27521320
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia.
    Danylesko I, Chowers G, Shouval R, Besser MJ, Jacoby E, Shimoni A, Nagler A, Avigdor A.
    Curr Res Transl Med; 2020 Jan 26; 68(1):17-22. PubMed ID: 31882377
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 54.